A Revolution in Alcohol Withdrawal Treatment
In today's world of healthcare innovation, Spark Biomedical has emerged as a frontrunner in developing cutting-edge, non-invasive neurostimulation devices. Recently, they received a significant boost in their mission by being awarded a $305,000 Phase I STTR grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA). This funding is earmarked for an important study aimed at evaluating the effectiveness of Spark's proprietary transcutaneous auricular neurostimulation (tAN®) technology. The goal? To potentially ease the distressing symptoms of alcohol withdrawal for individuals grappling with Alcohol Use Disorder (AUD).
Details of the Clinical Study
The Phase I clinical trial is set to take place in collaboration with two esteemed institutions: the Menninger Clinic and Baylor College of Medicine. During this pivotal study, tAN® therapy will be administered to patients undergoing a five-day inpatient alcohol withdrawal protocol. Researchers will closely observe several crucial clinical outcomes, including the severity of alcohol withdrawal symptoms as measured by the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar), the amount of benzodiazepine medication given, and the changes in alcohol cravings assessed via the Penn Alcohol Craving Scale (PACS).
Collaboration with Esteemed Partners
This grant comes at a time when securing NIH funding is incredibly competitive, making it all the more significant for Spark Biomedical. The company is deeply appreciative of the ongoing commitment from its collaborators, specifically the Menninger Clinic and Baylor College of Medicine, both renowned for their contributions to mental health and addiction treatment.
In Their Own Words
Mr. Daniel Powell, co-founder and CEO of Spark, shared his enthusiasm regarding the grant, stating, "Our mission has always been about utilizing neurostimulation to tackle some of the most pressing challenges in healthcare. Alcohol withdrawal is a particularly perilous phase in the recovery journey, and we believe patients deserve access to safer and more effective treatment options. This grant validates the necessity for innovation in this domain and highlights the confidence that NIH/NIAAA has in our technology. We're privileged to work alongside such respected partners. "
Innovative Approach to Healthcare
Dr. Navid Khodaparast, another key player at Spark and the principal investigator of this study, expressed his thoughts on the significance of the research. He remarked, "Exploring how tAN therapy can influence the treatment of AUD is critical. This study is an opportunity to unravel how brain responses are affected during alcohol withdrawal. By investigating not only the clinical outcomes but changes in brain connectivity, we aim to deepen our understanding of recovery from a neurological perspective."
Expanding the Horizon of Applications
Spark Biomedical’s current study on alcohol withdrawal represents an exciting expansion of their research portfolio into neurological health. Following the successful completion of this study, the company has plans to extend the use of tAN therapy beyond just opioid withdrawal, expanding its potential applications in the treatment of alcohol dependence as well.
About Spark Biomedical
Founded with the vision to revolutionize the medical device industry, Spark Biomedical, Inc. is dedicated to advancing bioelectronic medicine. The company focuses on creating innovative, wearable neurostimulation therapies aimed at enhancing neurological health, women's health, and hemostasis. Their team relies on a wealth of neuroscience and engineering expertise to empower healthcare practitioners with effective, evidence-based treatment solutions that address complex health scenarios where existing treatments may fall short. The company’s dedication has garnered support from esteemed federal bodies such as the NIH and DoD, exemplifying their commitment to enhancing the future of healthcare and technology.
About Menninger Clinic
The Menninger Clinic, founded in 1925 and affiliated with Baylor College of Medicine, is a leading entity in psychiatric and addiction treatment. It is recognized nationally for employing a biopsychosocial approach to address complex behavioral health challenges, especially in substance use disorders.
Frequently Asked Questions
What is the aim of Spark Biomedical's study?
The study aims to evaluate the safety and efficacy of Spark's tAN® technology in easing alcohol withdrawal symptoms for patients with Alcohol Use Disorder.
Who are the partners involved in this clinical trial?
Spark Biomedical is collaborating with Menninger Clinic and Baylor College of Medicine for this important clinical trial.
What will the study measure?
The study will track key outcomes including the severity of alcohol withdrawal symptoms, the amount of benzodiazepine medication administered, and changes in alcohol cravings.
Why is this grant important for Spark Biomedical?
The NIH/NIAAA grant is crucial as it validates the need for innovation in alcohol withdrawal treatment and demonstrates trust in Spark's technology.
What are the future plans for tAN therapy?
After this study, Spark plans to broaden the use of tAN therapy to also address alcohol withdrawal in addition to its initial focus on opioid withdrawal.
